IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
USD · NASDAQ:ALPXU
Issue Size
$12.00M
Price Range
$10.00
Shares
12.68M o/s · 2.4M offered
Listing Price
Alpex Acquisition Corporation (ALPX)
Alpex Acquisition Corporation focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2026 and is based in Wilmington, Delaware.
The company profile, business description, and key company details are provided by S&P Global Market Intelligence. The list of executives is sourced from SEC.gov. Recent SEC filings are sourced directly from SEC.gov.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Change from offer price to today
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:ALPXU
Key valuation ratios and metrics
Balance sheet strength and liquidity
Historical financial performance
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | $10.01 | $10.02 | $10.01 | $10.02 | $10.02 | +0.01 | 135,800 |
| 2026-06-26 | $10.00 | $10.01 | $9.99 | $9.99 | $9.99 | -0.01 | 597,000 |
| 2026-06-25 | $10.01 | $10.02 | $10.00 | $10.00 | $10.00 | -0.01 | 3,979,400 |
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 8-K | Jun 29, 2026 | Current Report |
| 424B4 | Jun 25, 2026 | Prospectus |
| EFFECT | Jun 24, 2026 | Notice of Effectiveness |
| CERT | Jun 24, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Jun 24, 2026 | Registration of securities |
| S-1/A | Jun 5, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | May 22, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Apr 10, 2026 | General form for registration of securities under the Securities Act of 1933 |
Contact and headquarters details
Key executives and officers
Daniel R Vlock, MD
President, Chief Executive Officer and Director
Thomas T. Thomas
Chief Financial Officer
Gerald B. Pier, PhD
Chief Scientific Officer
William W. Chin, MD
Senior Strategic Advisor, Director
Christine de los Reyes, PharmD, MBA
Chief Business Officer, Chief Commercialization Officer
Peter J. Werth
Director
$10.01
Listing date
Jun 25, 2026
Sector
Financials